ライフサイエンスコーパス: tumor resection

1 y (proctectomy, transanal local excision, no tumor resection).

2 esidual tumor and recurrence clonality after tumor resection.

3 and 74% had full recovery after therapy and tumor resection.

4 y express tumor markers and are decreased by tumor resection.

5 m five research subjects who underwent brain tumor resection.

6 tients with pancreatic cancer after complete tumor resection.

7 f treatment appear to be superior to upfront tumor resection.

8 d during the perioperative period of primary tumor resection.

9 t tissue, resulting in improved precision of tumor resection.

10 etastases and extends survival after primary tumor resection.

11 ng micrometastatic disease following primary tumor resection.

12 mize language deficits associated with brain-tumor resection.

13 initially cured by transsphenoidal pituitary tumor resection.

14 evaluated intracerebral CED of CB along with tumor resection.

15 lped to reduce the morbidity associated with tumor resection.

16 rse bone loss caused by trauma, disease, and tumor resection.

17 herapy including radiation, chemotherapy, or tumor resection.

18 70 RU per milliliter, which normalized after tumor resection.

19 ntensive care unit stay after craniotomy for tumor resection.

20 r growth, and minimal residual disease after tumor resection.

21 of life is not impaired following chest wall tumor resection.

22 term survival depends critically on complete tumor resection.

23 e, trauma, infection, radiation necrosis, or tumor resection.

24 f CD3+ cells in the spleen within 24-48 h of tumor resection.

25 rostate cancer ensues after complete primary tumor resection.

26 ce metastatic relapse after primary prostate tumor resection.

27 moderately increased survival after primary tumor resection.

28 high local recurrence rate due to incomplete tumor resection.

29 argins and perineural invasion to help guide tumor resection.

30 to simulate connectome disruption following tumor resection.

31 (9%) or within 5-8 weeks (91%) after primary tumor resection.

32 he peritumoral cortex of patients undergoing tumor resection.

33 le polymer scaffold implanted at the time of tumor resection.

34 000 to 3,000 nm) fluorescence imaging-guided tumor resection.

35 ention" treatment when aiming for sequential tumor resection.

36 RR, 0.74; 95% CI, 0.67-0.83; P < .001) after tumor resection.

37 P ICG ecosystem, which can instantly improve tumor resection.

38 AuPC allowed for complete and non-excessive tumor resection.

39 n, and patients who underwent biopsy without tumor resection.

40 ared to open surgery for spinal nerve sheath tumor resection.

41 179 of 217 (82.5%) CROSS patients underwent tumor resection.

42 Optical imaging informed successful tumor resection.

43 ical tools for the intrasurgical guidance of tumor resection.

44 or confirmatory mediastinoscopy followed by tumor resection.

45 no-observed-adverse-event level, followed by tumor resection.

46 ollowed by 1 realistic virtual reality brain tumor resection.

47 tive assessment in patients undergoing brain tumor resection.

48 ed increased survival of rats after surgical tumor resection.

49 Tumor resection.

50 here postoperative MRI suggested gross total tumor resection.

51 tical imaging have improved the precision of tumor resection.

52 assessing surgical margins for maximal safe tumor resection.

53 s administration of contrast material before tumor resection.

54 ke, and then on selected days after surgical tumor resection.

55 tended the survival of the treated mice post tumor resection.

56 ted this therapy several years after primary tumor resection.

57 for local treatment of GBM following maximal tumor resection.

58 me (<10 mm(3)) only possible by day 20 after tumor resection.

59 ed to assess factors associated with primary tumor resection.

60 ur due to periodontitis, trauma or following tumor resection.

61 ively assessed tumor adhesion at the time of tumor resection.

62 23,004 (60.9%) underwent palliative primary tumor resection.

63 IV CRC, 43,273 (67.4%) had undergone primary tumor resection.

64 ronavigated tissue-sampling procedure during tumor resection.

65 ted residual tumor after presumably complete tumor resection.

66 ally invasive surgery, will influence future tumor resections.

67 wed a detrimental outcome despite successful tumor resections.

68 Twenty-four patients had tumor resection (19 Whipple, four total pancreatectomy,

69 ending on whether they were to be treated by tumor resection, 5 weeks of CS-682 chemotherapy at 40-60

70 nts, 56 patients underwent pretreatment with tumor resection (71.8%), 49 patients received nonsomatos

71 Preoperatively before tumor resection a functional test battery [video head-im

72 st-line therapy consists of maximal surgical tumor resection, accompanied by chemotherapy and radioth

73 r oligometastatic (n = 72) disease underwent tumor resection after neoadjuvant treatment.

74 er, randomized data regarding immediate lung tumor resection after systematic endosonography versus a

75 ) and among patients treated with or without tumor resection (all P < .001).

76 d by either the tumor or subsequent surgical tumor resection altered head-on-trunk kinematics in a ma

77 luding checkpoint immunotherapies, and early tumor resection and (neo)adjuvant chemotherapy fails to

78 A total of 356 patients underwent tumor resection and 49 patients were readmitted within 3

79 om 232 patients (T3-4, N0, M0) with complete tumor resection and a median follow-up of 97 months was

80 In three cases, localized tumor resection and a variety of reconstructive techniqu

81 A combination of repeat tumor resection and adjuvant chemotherapy resulted in pr

82 metastatic disease many years after primary tumor resection and adjuvant therapy seems to arise from

83 followed by vascular reconstruction, ex vivo tumor resection and autotransplantation of excised organ

84 mg daily, started after potentially curative tumor resection and chemotherapy or radiotherapy as indi

85 imodality therapy with transurethral bladder tumor resection and cisplatin-based chemoradiation thera

86 oup of tumor-bearing animals by serial kill, tumor resection and counting of radioactivity in a gamma

87 went (18)F-fluorocholine PET/CT, followed by tumor resection and gene expression profiling.

88 with glioblastoma who subsequently underwent tumor resection and genetic testing.

89 Tumor resection and immunotherapy resulted in improvemen

90 Rates of primary tumor resection and median relative survival were calcul

91 igational systems, to evaluate the extent of tumor resection and modify surgery if necessary, to guid

92 importance for simultaneous applications in tumor resection and post-resection treatment of remainin

93 e patients and 1 male patient underwent iris tumor resection and presented to our service with suspic

94 are integrated into surgical practice during tumor resection and remain in situ only for the duration

95 Clinical use of the GAINS to guide tumor resection and sentinel lymph node mapping promises

96 Survival analysis of patients who underwent tumor resection and started adjuvant chemotherapy showed

97 December 31, 2010, who had undergone primary tumor resection and those who had not.

98 patients (29.0%) did not require additional tumor resection and were analyzed as a separate group.

99 euroblastoma resection, 170 (55.2%) a kidney tumor resection, and 123 (39.9%) an operation to treat b

100 aging allowed for guidance of intraoperative tumor resection, and a histological correlation validate

101 c immune changes were reversed with surgical tumor resection, and many were prevented by interleukin-

102 ly contributes to mortality following breast tumor resection, and meanwhile post-surgical bacterial w

103 ic evaluation at restaging), margin-negative tumor resection, and overall survival were evaluated usi

104 trated advanced diagnostic ability, enhanced tumor resection, and reduced tumor recurrence.

105 ho required re-irradiation, vitrectomies, or tumor resections; and those whose treatment was performe

106 t for all neurosurgical patients after brain tumor resection are not clear.

107 Although biopsies and tumor resection are prognostically beneficial for gliobl

108 ntially detected in the blood at the time of tumor resection as compared to routine follow-up.

109 ings revealed that MPO imaging could improve tumor resection as well as be a useful imaging biomarker

110 the completion of neoadjuvant therapies and tumor resection as well as to cancer survivors could eli

111 nts with eCs before and 6 to 13 months after tumor resection, as well as in in vitro glucocorticoid-t

112 for, symptomatic disease, with less than 50% tumor resection at diagnosis, or with unresectable progr

113 Five of 12 patients (42%) had a complete tumor resection at diagnosis.

114 ere found to be predictive for the extent of tumor resection at first (P < .001) and best (P < .001)

115 ften represents the only barrier to complete tumor resection at the time of pancreaticoduodenectomy.

116 eriments and observations, including primary tumor resection at week 9 and release from the treatment

117 aring mice relative to LPS-treated controls; tumor resection attenuated these effects in some cases (

118 efore, we tested the extent to which mammary tumor resection attenuates tumor-induced neuroinflammati

119 cellular carcinoma who had undergone radical tumor resection between 1999 and 2003.

120 tients who underwent pituitary or parasellar tumor resection between January 2009 to December 2018 we

121 ge II OCC in a curative intent (with primary tumor resection) between January 2000 and December 2015

122 ents with stage IV CRC had undergone primary tumor resection but, beginning in 2001, a trend toward f

123 t of the extent or the aggressiveness of the tumor resection by the neurosurgeon.

124 n pediatric HCC is more likely when complete tumor resection can be achieved.

125 Aggressive tumor resection can lead to the need for extensive recon

126 Intraoperative consultations, used to guide tumor resection, can present histopathological findings

127 chimeric 81C6 administered directly into the tumor resection cavities of brain tumor patients.

128 ing aCD47 can be directly deposited into the tumor resection cavity, enabling seamless hydrogel filli

129 stem cells increased their retention in the tumor resection cavity, permitted tumor-selective migrat

130 to CAR-T cells directly inoculated into the tumor resection cavity.

131 1, 2011, with complete data sets for RT, CT, tumor resection, Charlson-Deyo comorbidity scores, age,

132 levated in patients that underwent sub-total tumor resection compared to gross total resection and th

133 ssing tumors, allowing IGS and more complete tumor resection compared with white light surgery.

134 noma models, aCAP treatment after incomplete tumor resection contributes to inhibiting tumor growth a

135 The annual rate of primary tumor resection decreased from 74.5% in 1988 to 57.4% in

136 derwent AWR for ventral hernias or repair of tumor resection defects at a 710-bed tertiary cancer cen

137 ibody titers); two of three patients without tumor resection died of neurological deterioration.

138 nty-three of 46 patients (50%) who underwent tumor resection died.

139 nistered fish oil supplements before primary tumor resection, dietary intervention modulated the micr

140 gnificant predictive variables of incomplete tumor resection: diffuse tumor margin on T2-weighted MR

141 The association between the extent of tumor resection (EOR) and outcome remains undefined, not

142 w-grade glioma (LGG), the extent of surgical tumor resection (EOR) has a controversial role, in part

143 Tumor resection followed a minimum of three cycles.

144 All patients underwent tumor resection followed by a single intraparenchymal in

145 muscle-invasive bladder cancer (HR-NMIBC) is tumor resection followed by adjuvant Bacillus Calmette-G

146 reached or after 5 weeks underwent operative tumor resection, followed by monitoring for recurrence a

147 hemotherapeutic and biologic agents, primary tumor resection for patients with stage IV colorectal ca

148 nds in the use of neoadjuvant therapy before tumor resection for various types of cancer from 2004 to

149 ted along the surgical margin at the time of tumor resection, for achieving local and prolonged relea

150 n of language areas in a patient after brain tumor resection, from strong left-sided to symmetrical l

151 e to oncological interventions, particularly tumor resection, go hand in hand with cognitive outcome.

152 hen drug treatment was combined with primary tumor resection, greater than 60% of the mice were cured

153 (group 1, 60 patients) or SDRT combined with tumor resection (group 2, 18 patients).

154 he development of an intraoperative tool for tumor resection guidance with the aim of enabling oncolo

155 ypoplasia and the other with posterior fossa tumor resection-had markedly improved corneal sensation

156 congenital anomalies, infections, trauma, or tumor resection, how orofacial stem/progenitor cells con

157 reduced DDX5 exhibited poor prognosis after tumor resection, identifying DDX5 as an important player

158 with recurrent high-grade gliomas underwent tumor resection, implantation of an intracavitary reserv

159 he main variables associated with incomplete tumor resection in 101 patients were identified by using

160 etic ablation of SAA enhanced survival after tumor resection in a T cell-dependent manner.

161 evaluated at initial diagnosis), leading to tumor resection in all cases.

162 an important technique for ensuring complete tumor resection in malignant cancers.

163 s study was to determine outcomes of primary tumor resection in metastatic neuroendocrine tumors acro

164 ld MRI significantly increased the extent of tumor resection in this subgroup of malignant gliomas lo

165 mics profiling of samples from posttreatment tumor resections in the clinical trial and from another

166 of first line of GBM-treatment, we show that tumor-resection invigorates an anti-tumor response via i

167 nary function in lung cancer patients before tumor resection is essential for patient selection for s

168 nary function in lung cancer patients before tumor resection is essential for patient selection for s

169 However, maximization of the extent of tumor resection is hampered by difficulty in intraoperat

170 Primary chemotherapy with delayed tumor resection is increasingly advocated for patients w

171 In carefully selected patients, tumor resection is often possible; however, the perioper

172 Surgical tumor resection is often the only curative option for th

173 Although early after tumor cell inoculation tumor resection leads to the development of immunity, th

174 ase-free survival, disease relapse, positive tumor resection margins, and tumor stage at presentation

175 feasibility for detecting residual cancer on tumor resection margins, using a genetically engineered

176 w for enhanced intraoperative delineation of tumor resection margins.

177 However, primary tumor resection may still be overused, and current treat

178 Mechanical stimuli during tumor resection may therefore negatively impact patient

179 For symptomatic or growing tumors, resection may be curative.

180 Despite early tumor resection, mice died from locally recurring and di

181 l analysis suggested that SDRT with combined tumor resection might be associated with increased tumor

182 ry pathways with functional consequences and tumor resection mitigates most, but not all, of these ch

183 s tumor-injection model and the postsurgical tumor-resection model of 4T1 breast cancer.

184 tors, eliminated micrometastases in multiple tumor-resection models, resulting in long-term survival.

185 condary fracture repair (n = 3), or an after-tumor resection (n = 5).

186 Our results suggested that tumor resection not only led to the reversal of immune s

187 s suffered a traumatic injury or underwent a tumor resection of the lower or upper limb.

188 One hundred seventy-nine patients underwent tumor resection, of whom 30 with stage-I tumors and duod

189 e administered in the resection cavity after tumor resection on day 5 (Group B).

190 dy evaluated the impact of extent of primary tumor resection on local progression and survival and as

191 astatic neuroblastoma, the impact of primary tumor resection on outcome is a matter of medical debate

192 t because no studies have shown an effect of tumor resection on survival.

193 tigate the effect of drug administration and tumor resection on these quantities and predict the surv

194 ng, which is costly and only available after tumor resection or biopsy.

195 phy were randomly assigned to immediate lung tumor resection or confirmatory mediastinoscopy followed

196 of the fibular bone 3 to 6 months before jaw tumor resection or defect reconstruction.

197 Neurosurgery for brain tumor resection or epilepsy treatment requires a craniot

198 imarily demonstrated applicability following tumor resection or in immune-privileged tissues.

199 atment-naive patients with HCC who underwent tumor resection or liver transplant between September 20

200 tential curative options for this malignancy-tumor resection or organ transplantation.

201 n 40 years of age and had undergone subtotal tumor resection or who were 40 years of age or older, pr

202 cerous lesions, to delineate the margins for tumor resection, or as a feedback mechanism to assess re

203 tend through the jaws as a result of trauma, tumor resection, or congenital defects.

204 oup) and 7 patients had a planned orthopedic tumor resection (orthopedic surgery group).

205 nts were 158 consecutive postoperative brain tumor resection patients admitted to a neurocritical car

206 Tumor resection performed at this complex region poses a

207 Craniotomies for tumor resection performed with preoperative fMRI were as

208 re is a need to image excised tissues during tumor-resection procedures in order to identify residual

209 ned as chemotherapy and/or radiation without tumor resection, proctectomy, or transanal local excisio

210 adjuvant administration of gemcitabine after tumor resection prolonged survival.

211 conditioned syngeneic NK cells after primary tumor resection promoted long-term survival of mice with

212 ave fueled persistent uncertainty if primary tumor resection (PTR) before chemotherapy prolongs survi

213 The role of primary tumor resection (PTR) in synchronous patients with metas

214 Primary tumor resection (PTR) is recommended for patients with u

215 Primary tumor resection (PTR) may offer a survival benefit in me

216 Complete surgical tumor resection (R0) for treatment of intrahepatic chola

217 a significant change in trend in the primary tumor resection rate had occurred.

218 Despite the decreasing primary tumor resection rate, patient survival rates improved.

219 Primary tumor resection rates after neoadjuvant therapy and over

220 Difference in primary tumor resection rates over time.

221 ckade administered immediately after primary tumor resection reduces metastatic relapse from 97.4 to

222 for patients in remission following primary tumor resection remain limited.

223 Surgery with complete tumor resection remains the main treatment option for pa

224 Tumor resection remains the only curative treatment but

225 efficacy of Neuregen for treatment of brain tumor resections remains to be determined.

226 ultrasound implant was placed at the end of tumor resection replacing the bone flap.

227 ustained local TLR7/8 agonism at the time of tumor resection represents a promising approach for the

228 Twenty-seven patients underwent tumor resection (resectability rate 71%), of which 26 in

229 Tumor resection reversed these behavioral consequences,

230 al MPS and a trend toward increased MPB, and tumor resection reverses these derangements.

231 In patients with macroscopically complete tumor resection, RHT in addition to chemotherapy resulte

232 Results from histopathologic analysis after tumor resection served as the reference standard, and pa

233 Histopathologic results after subsequent tumor resection served as the reference standard, and pa

234 ere randomly assigned, 178 to immediate lung tumor resection (seven dropouts) and 182 to confirmatory

235 argeted sequencing assay was used to analyze tumor resection specimens, with a focus on BRAF V600E al

236 Surgical tumor resection, standard-of-care for glioblastoma, not

237 eatic cancer regardless of disease stage and tumor resection status (overweight patients: hazard rati

238 = 27 days) was significantly associated with tumor resection (STR/GTR), years of diagnosis after 2006

239 tested the extent to which mammary tumors or tumor resection ("survivors") in mice affects behavior a

240 s permits larger instruments and may improve tumor resection, the outcome is determined by tumor char

241 are associated with long-term survival post-tumor resection, they are not associated with responsive

242 urrent cases, the mean interval from initial tumor resection to detection of recurrence was 58 months

243 a with syngeneic transplantation and primary tumor resection to generate isogenic cells from primary

244 in VS patients, and may inform the timing of tumor resection to preserve hearing.

245 Adjuvant therapies were given after primary tumor resections to treat postsurgical regrowths and dis

246 e during the perioperative period of primary tumor resection, to confer protection against B16 melano

247 estigate the changes in ctDNA after surgical tumor resection, tumor and blood samples obtained before

248 and another following large posterior fossa tumor resection-underwent corneal sensory reconstruction

249 e CEUS imaging was performed during surgical tumor resection using an ultrasound machine (MyLab Twice

250 Local tumor resection using lamellar sclerouvectomy is mainly

251 patients with and without palliative primary tumor resection using risk-adjusted Cox proportional haz

252 5-year disease-specific survival rate after tumor resection was 65%.

253 Complete tumor resection was achieved in 34 patients (40%), inclu

254 lorectal cancer patients, palliative primary tumor resection was associated with improved overall and

255 opensity score matching, we found that gross tumor resection was associated with longer progression-f

256 Tumor resection was attempted.

257 ltivariate analyses revealed that incomplete tumor resection was due to tumor involvement of the cort

258 8 patients with stage III or IV disease, and tumor resection was possible in two (10%) of the remaini

259 Finally, the extent of tumor resections was correlated with local control rate

260 inning in 2001, a trend toward fewer primary tumor resections was seen.

261 Factors associated with primary tumor resection were age younger than 50 years, female s

262 ents with Stage IV CRC who underwent primary tumor resection were analyzed.

263 t the tumor core and invasive rim of a human tumor resection were compared.

264 patients from the ESOPEC trial who underwent tumor resection were eligible.

265 erred for functional MR imaging for possible tumor resection were prospectively evaluated.

266 es (SNs) and non-SNs obtained during primary tumor resection were sectioned at multiple levels and st

267 Seven samples of tumor resections were excluded from the study because th

268 T before and after chemotherapy, followed by tumor resection, were retrospectively reviewed.

269 substantial recovery after immunotherapy and tumor resection when appropriate.

270 enic effects on the NMDAR, immunotherapy and tumor resection, when appropriate, are often effective.

271 al margins occur in a significant portion of tumor resections, which is directly correlated with a po

272 n goal of brain tumor surgery is to maximize tumor resection while preserving brain function.

273 primary goal of neurosurgery is to maximize tumor resection while sparing eloquent cortices adjacent

274 The likelihood of complete tumor resection with a negative microscopic margin and c

275 To study language function after brain-tumor resection with language mapping, we examined 250 c

276 Prior tumor resection with lateral wall osteotomy and failure

277 Prior tumor resection with lateral wall osteotomy, delay in IA

278 the presence of unforeseen N2 disease after tumor resection with lymph node dissection.

279 We achieved a complete tumor resection with negative margins in all cases.

280 surgical management which included complete tumor resection with preservation of the globe to allow

281 compared with 51% in patients with complete tumor resection with residual tumor (P =.03).

282 ts underwent FDG PET/CT imaging before local tumor resection with selective or complete neck dissecti

283 ong patients with normal CRP levels, radical tumor resection within multimodality therapy was associa

284 eved after radical prostatectomy is complete tumor resection without recurrence and full recovery of

285 panded stromal progenitors from patient lung tumor resections without complex sorting methods or grow

286 Eighteen of 27 patients (63%) with complete tumor resection (without LTX) and 20 of 34 patients (59%

287 relapse when placed in the surgical area of tumor resection, without any collateral toxicity.